Meta-Analysis
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2021; 9(30): 9090-9100
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9090
Clinical significance of breast cancer susceptibility gene 1 expression in resected non-small cell lung cancer: A meta-analysis
Yang Gao, Xiao-Di Luo, Xiao-Li Yang, Dong Tu
Yang Gao, Xiao-Di Luo, Xiao-Li Yang, Dong Tu, Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China, Kunming 650032, Yunnan Province, China
Author contributions: Tu D made substantial contributions to the conception and design of the work; Gao Y and Luo XD searched and selected the materials, extracted the data, and wrote this manuscript; Yang XL and Tu D revised the paper carefully and also contributed to the statistical analysis; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Tu, MD, Professor, Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China, No. 212 Daguan Road, Xishan District, Kunming 650032, Yunnan Province, China. tudongyisheng@126.com
Received: March 30, 2021
Peer-review started: April 1, 2021
First decision: June 23, 2021
Revised: June 25, 2021
Accepted: September 2, 2021
Article in press: September 2, 2021
Published online: October 26, 2021
Processing time: 205 Days and 5.4 Hours
Abstract
BACKGROUND

The clinical significance of breast cancer susceptibility gene 1 (BRCA1) in non-small cell lung cancer (NSCLC) patients undergoing surgery remains unclear up to now.

AIM

To explore the relation of BRCA1 expression with clinicopathological characteristics and survival in patients with resected NSCLC.

METHODS

EMBASE, PubMed, Web of Science, and The Cochrane Library databases were searched to identify the relevant articles. To assess the correlation between the expression of BRCA1 and clinicopathological characteristics and prognosis of patients with resected NSCLC patients, the combined relative risks or hazard ratios (HRs) with their corresponding 95% confidence intervals [CIs] were estimated.

RESULTS

Totally, 11 articles involving 1041 patients were included in the meta-analysis. The results indicated that the expression of BRCA1 was significantly correlated with prognosis of resected NSCLC. Positive BRCA1 expression signified a shorter overall survival (HR = 1.60, 95%CI: 1.25-2.05; P < 0.001) and disease-free survival (HR = 1.78, 95%CI: 1.42-2.23; P < 0.001). However, no significant association of BRCA1 expression with any clinicopathological parameters was observed.

CONCLUSION

BRCA1 expression indicates a poor prognosis in resected NSCLC patients. BRCA1 might serve as an independent biomarker to predict clinical outcomes and help to customize optimal adjuvant chemotherapy for NSCLC patients who had received surgical therapy.

Keywords: Breast cancer susceptibility gene 1; Non-small cell lung cancer; Clinicopathological characteristics; Prognosis; Surgery; Meta-analysis

Core Tip: Based on 11 included articles involving 1041 patients, we demonstrated that the expression of the breast cancer susceptibility gene 1 (BRCA1) was significantly correlated with prognosis of resected non-small cell lung cancer (NSCLC). Furthermore, positive BRCA1 expression signified a shorter overall survival and disease-free survival. However, no significant association of BRCA1 expression with any clinicopathological parameters was observed. Overall, BRCA1 expression indicates a poor prognosis in resected NSCLC patients. BRCA1 might serve as an independent biomarker to predict clinical outcomes and help to customize optimal adjuvant chemotherapy for NSCLC patients who had received surgical therapy.